HC Wainwright Has Pessimistic Outlook of HRTX Q3 Earnings

Key Points

• HC Wainwright lowered Heron Therapeutics’ Q3 2026 EPS estimate to a loss of $0.03 per share from $0.02 and maintained a “Neutral” rating. The firm projects continued losses through 2029, with profitability beginning in 2030.
• Heron reported a Q2 loss of $0.03 per share and revenue of $37.67 million, below analysts’ $42.19 million estimate. The company also posted a negative net margin of 22.52% and negative return on equity of 265.11%.
• Heron shares traded around $0.34, despite gaining 5.3%, near their 52-week low of $0.30. Analysts’ average rating is “Hold,” with a consensus price target of $2.00, while institutional investors own approximately 80% of the stock.

Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) - HC Wainwright lowered their Q3 2026 EPS estimates for Heron Therapeutics in a report issued on Tuesday, August 11th. HC Wainwright analyst B. Folkes now expects that the biotechnology company will post earnings per share of ($0.03) for the quarter, down from their prior estimate of ($0.02). HC Wainwright has a "Neutral" rating on the stock. The consensus estimate for Heron Therapeutics' current full-year earnings is ($0.09) per share. HC Wainwright also issued estimates for Heron Therapeutics' Q4 2026 earnings at ($0.03) EPS, FY2026 earnings at ($0.14) EPS, FY2027 earnings at ($0.12) EPS, FY2028 earnings at ($0.06) EPS, FY2029 earnings at ($0.01) EPS and FY2030 earnings at $0.01 EPS.

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last announced its earnings results on Monday, August 10th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter. Heron Therapeutics had a negative return on equity of 265.11% and a negative net margin of 22.52%.The business had revenue of $37.67 million for the quarter, compared to analyst estimates of $42.19 million.

A number of other research analysts have also recently commented on HRTX. Zacks Research upgraded Heron Therapeutics from a "strong sell" rating to a "hold" rating in a research report on Monday, August 3rd. Wall Street Zen raised shares of Heron Therapeutics to a "sell" rating in a research report on Saturday, August 8th. Needham & Company LLC downgraded shares of Heron Therapeutics from a "buy" rating to a "hold" rating in a research note on Tuesday, June 2nd. Finally, Weiss Ratings reissued a "sell (e+)" rating on shares of Heron Therapeutics in a report on Friday, July 17th. One analyst has rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Heron Therapeutics currently has an average rating of "Hold" and a consensus price target of $2.00.

Heron Therapeutics Trading Up 5.3%

Shares of NASDAQ:HRTX opened at $0.34 on Thursday. The business's 50 day simple moving average is $0.44 and its 200 day simple moving average is $0.81. The company has a market capitalization of $64.53 million, a P/E ratio of -1.79 and a beta of 1.65. The company has a debt-to-equity ratio of 17.51, a current ratio of 2.53 and a quick ratio of 1.51. Heron Therapeutics has a 1 year low of $0.30 and a 1 year high of $1.57.

Hedge Funds Weigh In On Heron Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Goldman Sachs Group Inc. boosted its stake in shares of Heron Therapeutics by 57.0% during the first quarter. Goldman Sachs Group Inc. now owns 1,028,678 shares of the biotechnology company's stock valued at $2,263,000 after purchasing an additional 373,518 shares in the last quarter. JPMorgan Chase & Co. increased its stake in shares of Heron Therapeutics by 36.8% in the second quarter. JPMorgan Chase & Co. now owns 953,080 shares of the biotechnology company's stock valued at $1,973,000 after buying an additional 256,637 shares during the period. Rhumbline Advisers increased its stake in shares of Heron Therapeutics by 29.3% in the second quarter. Rhumbline Advisers now owns 222,438 shares of the biotechnology company's stock valued at $460,000 after buying an additional 50,344 shares during the period. Prudential Financial Inc. raised its holdings in Heron Therapeutics by 231.0% in the 2nd quarter. Prudential Financial Inc. now owns 36,465 shares of the biotechnology company's stock valued at $75,000 after buying an additional 25,450 shares during the last quarter. Finally, Russell Investments Group Ltd. bought a new position in Heron Therapeutics in the 2nd quarter valued at approximately $43,000. Institutional investors and hedge funds own 80.01% of the company's stock.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and commercializing therapies in pain management and supportive care for patients undergoing medical and surgical procedures. The company's research is dedicated to addressing unmet needs in oncology supportive care and post-operative pain management through innovative drug formulations designed to improve patient outcomes and reduce reliance on opioids.

Heron's first approved therapy, SUSTOL (granisetron) extended-release injection, received U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source